Privigen

Known as: Venimmune 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
AIM A pharmacoeconomic analysis of direct costs on treatment with high dose intravenous immunoglobulins (IVIG) and plasmapheresis… (More)
Is this relevant?
2014
2014
BACKGROUND AND OBJECTIVES Activated clotting factor FXI (FXIa) has been postulated to play a significant role in thromboembolic… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2014
2014
IntroductionHemolysis is considered a class effect and a rare adverse event that can occur following therapy with human normal… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
BACKGROUND AND PURPOSE High dose intravenous immunoglobulin (IVIG) is an established treatment for various neuromuscular… (More)
Is this relevant?
2013
2013
This prospective, multicenter, single-arm, open-label Phase III study aimed to evaluate the efficacy and safety of Privigen… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2011
2011
  • P & T : a peer-reviewed journal for formulary…
  • 2011
Ready-to-use 10% liquid IVIg Room temperature storage up to 36 months Sophisticated. First and only IVIg stabilized with proline… (More)
  • table 2
  • table 3
  • table 2
  • table 2
  • table 3
Is this relevant?
2009
2009
Intravenous immunoglobulin (IVIG) has become a mainstay of treatment for acute and chronic immune thrombocytopenic purpura (ITP… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
2009
2009
The objective of this prospective, open-label, single-arm, Phase III study was to assess the efficacy and safety of Privigen… (More)
Is this relevant?
2009
2009
2009
BACKGROUND AND OBJECTIVES IgPro10 (Privigen) is a new liquid intravenous immunoglobulin (IVIG) product that is formulated with… (More)
Is this relevant?